Industries > Pharma > Generic Drugs Market Forecast 2016-2026
Generic Drugs Market Forecast 2016-2026
Growth in Leading Regional and National Markets
What can be expected from the Generic Drugs Market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
Our 306-page report provides 175 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national generic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.
See detailed profiles or revenue forecasts for some of the leading regions in the generic drugs market
• US
• EU5
• Asia-Pacific
• Emerging markets
See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including:
• US
• Germany
• UK
• France
• Italy
• Spain
• China
• Japan
• India
• Brazil
• Russia
• Mexico
• South Korea
• Turkey
Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Generic Drugs Market will reach $254.6bn in 2016. We predict a high revenue growth over the forecast period driven by an ageing population, healthcare cost saving strategies and rapid growth of emerging economies.
Our work analyses the key companies in the market. See Visiongain’s analysis of ten leading companies, including:
• Teva
• Novartis (Sandoz)
• Allergan
• Mylan
• Pfizer
• Abbott
• Sun Pharma
• Aspen
• Fresenius Kabi
• Sanofi
A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Generic drugs revenue and share of total revenue
• Historic revenue (where available), analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the generic drugs industry?
Our new report discusses issues and events affecting the generic drugs market. You will find discussions, including qualitative analyses:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future generic drug opportunities
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets report helps you
In summary, our 306-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Generic Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for major regional markets – US, EU5, Asia-Pacific, Emerging markets
• Revenue forecasts to 2026 for fourteen leading national markets – US, Germany, UK, France, Italy, Spain, China, Japan, India, Brazil, Russia, Mexico, South Korea and Turkey
• Assessment of leading companies – analysis of products, revenue (where available), mergers & acquisitions, and pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the generic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Generic Drugs: Market Overview
1.2 Global Generic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. An Introduction to Generic Drugs
2.1 An Introduction to the Rise of Generic Drugs
2.2 What Are Generic Drugs?
2.2.1 Generic Active Ingredients
2.3 A Brief Overview of the Pharmaceutical Industry
2.3.1 Brief History of Generic Drugs
2.3.2 The Hatch-Waxman Act: The Rise of Generics
2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics
2.5 Types of Generics – Authorised, Branded and Unbranded
2.6 Complex Generics
2.7 Classification of Generic Drugs Markets
2.8 Is Generic Substitution Bad News for Big Pharma Business?
2.8.1 The 'Evergreening' of Pharmaceutical Products
2.9 Regulation of Generic Drugs
2.9.1 Regulation in the US
2.9.2 Regulation in Europe
2.9.3 Regulation in Japan
2.9.4 Regulation in China
2.10 Compulsory Licensing
2.11 Market Definition and Scope of This Report
2.11.1 Market Sizing and Revenue Reporting
2.11.2 Currency Exchange Rates in This Report
3. Generic Drugs Market 2016-2026
3.1 The Global Generic Drugs Market: Market Overview
3.1.1 Segmenting the Global Generic Drugs Market
3.2 The Rise of the Global Generic Drugs Market in 2015
3.3 Changes in the Regional Distribution of the Generic Drugs Market 2014-2015
3.4 The Global Generic Drugs Market: Sales Forecast 2016-2026
3.5 Generic Drugs: Regional Market Forecast: 2016-2026
3.5.1 Changes in Generic Drug Regional Market Shares 2016-2026
3.6 Leading National Markets for Generic Drugs: Market Forecast 2016-2026
3.7 National Markets that will Drive Generic Drugs Growth
3.8 Changes in Market Shares by National Market 2016-2026
3.9 Drivers and Restraints for the Global Generic Drugs Market 2016-2026
4. US Generic Drugs Market, 2016-2026
4.1 Generic Drugs in the US: Market Overview
4.1.1 The Effects of Generics on Healthcare Spending in the US
4.1.2 The Hatch-Waxman Act and Its Ongoing Effects
4.1.3 Consolidation in the Drug Development and Supply Chain Driving US Generics
4.2 US Historical Generic Penetration Rates
4.3 Leading Companies Operating within the US Generic Drugs Market
4.3.1 The Increasing Acceptance of Generics amongst Consumers
4.3.2 Affordable Care Act: Expanding Medicare Coverage
4.4 The US Generic Drugs Market: Drivers and Restraints 2016-2026
4.5 The US Generic Drugs Market Forecast: 2016-2026
4.6 The US Generic Drugs Market – Strategic Analysis
4.6.1 Will Biosimilars Dictate the Future of the US Generics Market?
4.6.2 The Backlog of ANDA Applications
4.6.3 The Generic Drug User Fee Amendments (GDUFA)
4.6.4 Shortages of Generic Drugs Will Restrain the Market
4.6.5 The Anti-Competitive ‘Pay for Delay’ Effect
4.7 US Generic Drugs Market: A Range of Factors Contributing to Growth
5. Leading European Generic Drug Market, 2016-2026
5.1 European Generic Drugs: Market Overview
5.1.1 The EU5
5.1.2 Why Growth in Some Markets is Being Hindered?
5.1.3 Predominant Pricing Systems and Generic Penetration In European Markets
5.1.4 Will Europe Move towards Free-Pricing Systems?
5.1.5 Challenges in the European Regulatory Environment
5.1.6 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe
5.1.7 FDA and EMA Joint Data Sharing and Inspections
5.2 EU5 Generic Drugs Market Forecast: 2016-2026
5.3 EU5 Market Share Breakdown 2016-2026
5.4 Germany: New Reforms to Medicinal Pricing May Impact Market Entry
5.4.1 German Generic Drugs Market: Generic Penetration By Volume, 2000-2015
5.4.2 German Generic Drugs Market: Generic Penetration by Value, 2000-2015
5.5 UK Generic Drugs Market: A Mature Market with Growth Potentials
5.5.1 UK Generic Drugs Market: Sales Forecast 2016-2026
5.5.2 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
5.5.3 UK Generic Drugs Market: Generic Penetration by Volume, 2000-2015
5.5.4 UK Generic Drugs Market: Generic Penetration by Value, 2000-2015
5.5.5 Pharmacists as Enforcers of Generic Substitution
5.5.6 Pay Time for ‘Pay-For-Delay’
5.5.7 GSK: Widening the Gate to Accessible Medicines
5.6 French Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
5.6.1 French Generic Drugs Market: Sales Forecast 2016-2026
5.6.2 French Generic Drugs Market: Generic Penetration by Volume, 2000-2015
5.6.3 French Generic Drugs Market: Generic Penetration by Value, 2000-2015
5.7 Italian Generic Drugs Market: Branded Generics Hindering Overall Growth
5.7.1 The Tightening of Italy’s Patent Legislations
5.7.2 The Italian Healthcare System – A Tale of Falling Budgets
5.7.3 Italian Generic Drugs Market: Sales Forecast: 2016-2026
5.7.4 Italian Generic Drugs market: Generic Penetration by Volume
5.7.5 Italian Generic Drugs Market: Generic Penetration by Value
5.8 Spain
5.8.1 Cost-Containment Measures Helping to Boost Generic Drug Use
5.8.2 Spanish Generic Drugs Market: Sales Forecast 2016-2026
5.8.3 Spanish Generic Drugs Market: Generic Penetration by Volume, 2000-2015
5.8.4 Spanish Generic Drugs Market: Generic Penetration by Value, 2000-2015
6. Asia-Pacific Generic Drugs Market, 2016-2026
6.1 Generic Drugs in the Asia-Pacific Market: Market Overview
6.2 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
6.2.1 The Major Drivers of Growth in the Chinese Generics Market
6.2.2 Chinese Generic Drugs Market: Sales Forecast 2016-2026
6.2.3 Compulsory Licensing of Generic Drugs
6.2.4 Expansion of Healthcare Coverage and Reimbursement
6.2.5 Chinese Generic Drugs Market: Generic Penetration by Volume, 2000–2015
6.2.6 Chinese Generic Drugs Market: Generic Penetration by Value, 2000-2015
6.2.7 The Impacts of Price Controls and the Anhui Model
6.3 Japanese Generic Drugs Market: High Barriers to Entry
6.3.1 Public Perception of Generics in Japan
6.3.2 Japanese Generic Drugs Market: Leading Companies
6.3.3 Japanese Generic Drugs Market: Sales Forecast 2016-2026
6.3.4 Japanese Generic Drugs Market: Generic Penetration by Volume, 2000–2015
6.3.5 Japanese Generic Drugs Market: Generic Penetration by Value, 2000-2015
6.3.6 Government Initiatives Driving Generic Penetration
6.3.7 Japanese Attitudes to Generic Drugs
6.4 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
6.4.1 Leading Companies in the Indian Generic Drugs Market
6.4.2 Indian Generic Drugs Market: Sales Forecast 2016-2026
6.4.3 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
6.4.4 Expansion of the National Healthcare Coverage Increases the Need for Generics
6.4.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?
7. Emerging Generic Drugs Market, 2016-2026
7.1 Generic Drugs in the Emerging Market: Market Overview
7.1.1 Emerging Economies: Improving Logistics and Better Infrastructure Catalysing Generics Growth
7.2 Brazil
7.2.1 Brazilian Generic Drugs Market: Sales Forecast 2016-2026
7.2.2 Generics to Facilitate Low-Income Earner’s Access to Medicines
7.2.3 Foreign Generic Drug Manufacturers Entering the Brazilian Market
7.3 Russian Generic Drugs Market: Improving IP Protection to Aid Market Growth
7.3.1 Historical Trends in Russia’s Pharmaceutical Production and Distribution
7.3.2 The Pharma2020 Strategy - Healthcare and Industry Reform
7.3.3 Self-Medication in Russia and the Integral Role of Pharmacies
7.3.4 Russian Generic Drugs Market: Sales Forecast 2016-2026
7.4 Mexico
7.4.1 Government Programmes to Vitalise Generic Penetration in Mexico
7.4.2 Regulatory Changes and the Inception of COFEPRIS
7.4.3 Mexican Generic Drugs Market: Sales Forecast 2016-2026
7.5 South Korea
7.5.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
7.5.2 South Korean Generic Drugs Market: Sales Forecast 2016-2026
7.6 Turkey
7.6.1 Cost Cutting Measures and their Effects on Turkish Generics
7.6.2 Will Turkey Become a Production Base for High Technology Products?
7.6.3 Turkish Generic Drugs Market: Sales Forecast 2016-2026
7.6.4 Regulatory Guidelines for Generic Drugs in Turkey
7.6.5 How Effective has Turkey’s Health Transformation Programme Been?
8. Leading Companies in the Generic Drugs market, 2016-2026
8.1 Generic Drugs: Continuous Expansion to Rival
8.1.1 The Leading Companies in the Global Generics Market
8.2 Teva
8.2.1 Teva: Historical Financial and Performance Analysis, 2010-2014
8.2.2 Teva Generic Drugs Sales Forecast 2016-2026
8.2.3 Teva and Allergan Spin-Off Generic Drug Deal
8.2.4 Allergan: Historical Financial and Performance Analysis, 2010-2014
8.2.5 Allergan: Developments in Generic Drug Segment Prior Mega-Deal
8.2.6 Teva: Generic Drugs Portfolio Analysis, 2016
8.2.7 Teva: What Future Moves Could We Expect?
8.3 Novartis
8.3.1 Novartis: Historical Financial and Performance Analysis, 2010-2014
8.3.2 Novartis Generic Drugs Sales Forecast 2016-2026
8.3.3 Novartis Generic Drugs Portfolio Analysis, 2016
8.3.4 What Does the Future Hold for Novartis’ Generic Drugs Business?
8.4 Mylan
8.4.1 Mylan: Historical Financial and Performance Analysis, 2010-2014
8.4.2 Mylan Generic Drugs Sales Forecast 2016-2026
8.4.3 Mylan: Recent Developments
8.4.4 Mylan’s Collaborative Efforts
8.4.5 What Does the Future Hold for Mylan’s Generic Drugs Business?
8.5 Pfizer
8.5.1 Pfizer: Historical Financial and Performance Analysis, 2010-2014
8.5.2 Pfizer’s Restructuring Strategy
8.5.3 Pfizer’s Done Deal with Hospira
8.5.4 Pfizer Generic Drugs Sales Forecast 2016-2026
8.5.5 Hospira: A Brief Overview of Operations
8.5.6 Hospira: Historical Financial and Performance Analysis 2010-2014
8.5.7 Hospira: Recent Developments
8.5.8 Future Prospects for Pfizer’s Generic Business
8.6 Abbott
8.6.1 Abbott: Historical Financial and Performance Analysis, 2010-2014
8.6.2 Abbott Generic Drugs Sales Forecast 2016-2026
8.6.3 Abbott: Recent Developments
8.6.4 What Does the Future Hold for Abbott’s Generic Drugs Business?
8.7 Sun Pharma
8.7.1 Sun Pharma’s Business Areas
8.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2010-2014
8.7.3 Sun Pharma Generic Drugs Sales Forecast 2016-2026
8.7.4 Sun Pharma-Ranbaxy Acquisition
8.8 Aspen
8.8.1 Aspen: Historical Financial and Performance Analysis, 2010-2014
8.8.2 Aspen Generic Sales Forecast 2016-2026
8.8.3 Aspen: Recent Developments
8.8.4 Future Outlook for Aspen’s Generic Business
8.9 Fresenius Kabi
8.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2010-2014
8.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2016-2026
8.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
8.9.4 Fresenius Kabi’s Joint Venture with PT Soho Global Health
8.9.5 Future Prospects for Fresenius Kabi’s Generics Business
8.10 Sanofi
8.10.1 Sanofi: Historical Financial and Performance Analysis, 2010-2014
8.10.2 Sanofi Generic Sales Forecast 2016-2026
8.10.3 Sanofi’s Response to Lantus Competition
8.10.4 Sanofi’s Strategies to Develop Generic Sales
8.10.5 Future Prospects for Sanofi’s Generics Business
9. Qualitative Analysis of the Generic Drugs Market, 2016-2026
9.1 Market Factors Influencing the Global Generic Drugs Market
9.2 SWOT Analysis of the Global Generic Drugs Market, 2016-2026
9.2.1 Strengths
9.2.2 Weaknesses
9.2.3 Opportunities
9.2.4 Threats
9.3 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2016-2026
9.3.1 Power of Buyers: Medium
9.3.2 Power of Suppliers: Low
9.3.3 Rivalry among Competitors: High
9.3.4 Threat of New Entrants: High
9.3.5 Threat of Substitutes: Low
10. Conclusions
10.1 Overview of Current Market Conditions and Market Forecast, 2016-2026
10.2 Generic Drugs as a Strategic Tool in Healthcare
10.3 Major Drivers of Growth for Generic Drugs, 2016-2026
10.4 The Regulatory Landscape for Generic Drugs
10.5 Leading Generic Drug Manufacturers
10.6 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2016-2026
10.7 Generic Penetration by Volume in Leading National Markets
10.8 What Does The Future Hold For The Global Generic Drugs Market?
11. Glossary
Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
List of Tables
Table 1.1 Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Markets, 2014-2026 (Redacted Data)
Table 2.1 Types Of Drug Names, 2016
Table 2.2 Currency Exchange Rates, 2015
Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Leading National Markets, 2014 and 2015
Table 3.2 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Region, 2014 and 2015
Table 3.3 The Global Generic Drugs Market Forecast:: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 3.4 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2014-2026
Table 3.5 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2014, 2020, and 2026
Table 3.6 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2014-2026
Table 3.6 (cont’d) The Global Generic Drugs Market Forecast:: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2014-2026
Table 3.7 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2020, 2020-2026, 2014-2026
Table 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2014, 2020, and 2026
Table 3.9 Global Generic Drugs Market Drivers and Restraints, 2014-2026
Table 4.1 US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2004-2015
Table 4.2 US Generic Drugs Market Drivers and Restraints, 2016-2026
Table 4.3 US Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.1 The EU5 Generic Drugs Market: Revenue ($bn) and Market Share (%) by Country, 2014 and 2015
Table 5.2 EU5 Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.3 The EU5 Generic Drugs Market: Market Share (%) by Country, 2014, 2020, 2026
Table 5.4 The German Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.5 German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.6 German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 5.7 The UK Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.8 UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.9 UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 5.10 The French Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.11 French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.12 French Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 5.13 The Italian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.14 Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.15 Italian Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 5.16 The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and (CAGR%), 2014-2026
Table 5.17 Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 5.18 Spanish Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 6.1 The Chinese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 6.3 Chinese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 6.4 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 6.5 Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Table 6.6 Japanese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Table 6.7 The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 6.8 Leading Drug Types In Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2015, 2020 & 2026
Table 7.1 The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.2 The Russian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.3 The Mexican Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.4 The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.5 The Turkish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2014
Table 8.2 Teva: Company Overview, 2014-2015
Table 8.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2009-2013
Table 8.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.5 Allergan: Company Overview 2014-2015
Table 8.6 Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.7 Novartis: Overview, 2014-2015
Table 8.8 Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.9 Novartis Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.10 Mylan: Company Overview, 2014-2015
Table 8.11 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.12 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.13 Pfizer: Company Overview, 2014-2015
Table 8.14 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.15 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.16 Hospira: Company Overview, 2013-2014
Table 8.17 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2010-2014
Table 8.18 Allergan: Company Overview, 2014-2015
Table 8.19 Abbott: Company Overview, 2014-2015
Table 8.20 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.21 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.22 Sun Pharmaceuticals: Company Overview, 2014-2015
Table 8.23 Sun Pharma: Historical Generic Drugs Sales (Rs.bn and $bn), 2010-2014
Table 8.24 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.25 Aspen: Company Overview, 2014-2015
Table 8.26 Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2010-2014
Table 8.27 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.28 Fresenius Kabi: Company Overview, 2014-2015
Table 8.29 Fresenius Kabi: Historical Generic Drugs Sales (€bn and $bn), 2010-2014
Table 8.30 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.31 Sanofi: Company Overview, 2014-2015
Table 8.32 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Table 8.33 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 9.1 SWOT Analysis of the Generic Drugs Market, 2016-2026
Table 9.2 World 65+ Population Forecast: Size (m), AGR (%) and CAGR (%), 2014-2026
Table 10.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2014, 2020 and 2026
Table 10.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2015
Table 10.3 Global Generic Drugs Market Forecast: Revenue ($bn) by National Markets, 2014, 2020 and 2026
Table 10.4 US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Table 10.5 BRIC Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Table 10.6 Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Table 10.7 Generic Drug Penetration by Volume in Leading National Markets (%), 2015
List of Figures
Figure 1.1 Global Generic Drugs Market Segmentation
Figure 2.1 EU Data Exclusivity for Generics: Possible Scenarios, 2016
Figure 3.1 The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2014
Figure 3.2 The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2015
Figure 3.3 The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2014
Figure 3.4 The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2015
Figure 3.5 Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2014-2026
Figure 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2014
Figure 3.7 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2020
Figure 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2026
Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2020
Figure 3.10 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2020-2026
Figure 3.11 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2026
Figure 3.12 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2014
Figure 3.13 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2020
Figure 3.14 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2026
Figure 4.1 US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2004-2015
Figure 4.2 US Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 5.1 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2014
Figure 5.2 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2015
Figure 5.3 Germany, France, UK, Italy, and Spain Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 5.4 The EU5 Generic Drugs Market: Market Share (%) by Country, 2014
Figure 5.5 The EU5 Generic Drugs Market: Market Share (%) by Country, 2020
Figure 5.6 The EU5 Generic Drugs Market: Market Share (%) by Country, 2026
Figure 5.7 The German Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.8 German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.9 German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 5.10 The UK Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.11 UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.12 UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 5.13 The French Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.14 French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.15 French Generic Drugs Market: Generic Penetration by Value (%), 2000-2015
Figure 5.16 The Italian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.17 Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.18 Italian Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 5.19 The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) , 2014-2026
Figure 5.20 Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 5.21 Spanish Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 6.1 China, Japan and India Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 6.2 The Chinese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 6.3 Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
Figure 6.4 Chinese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
Figure 6.5 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 6.6 Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2000-2015
Figure 6.7 Japanese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%) 2000-2015
Figure 6.8 The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 6.9 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2015
Figure 6.10 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2020
Figure 6.11 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2026
Figure 7.1 Brazil, Russia, Mexico, South Korea and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 7.2 The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 7.3 The Russian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 7.4 The Mexican Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 7.5 The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
Figure 7.6 The Turkish Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2014
Figure 8.2 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2015
Figure 8.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.4 Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.5 Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.6 Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.7 Novartis Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.8 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.9 Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.10 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.11 Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.12 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2010-2014
Figure 8.13 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.14 Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.15 Sun Pharma: Historical Generic Drugs Sales (Rs.bn) and AGR (%), 2010-2014
Figure 8.16 Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.17 Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.18 Aspen: Historical Revenue ($bn) and AGR (%), 2010-2014
Figure 8.19 Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.20 Fresenius Kabi: Historical Generic Drugs Sales (€bn) and AGR (%), 2010-2014
Figure 8.21 Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.22 Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.23 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
Figure 8.24 Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 9.1 World 65+ Population Forecast: Size (m) and AGR (%), 2014-2026
Figure 9.2 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2016
Figure 10.1 Global Generic Drugs Market Forecast: Revenue ($bn), 2014, 2020 and 2026
Figure 10.2 US, Japan and EU5 Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 10.3 BRIC Generic Drugs Market Forecast: ($bn), 2014-2026
Figure 10.4 Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
Figure 10.5 Generic Drug Penetration by Volume in Leading National Markets (%), 2015
Abbott
AbbVie
Actavis
Alcon (Novartis)
Allergan (Actavis)
Amgen
Anda Inc
APP Pharmaceuticals
Arrow Group (Actavis)
Ascent Pharmahealth (Actavis)
ASKA Pharmaceuticals
Aspen
AstraZeneca
Bergamo (Amgen)
Bioniche Pharma (Mylan)
BMP Sunstone (Sanofi)
CFR Pharmaceuticals (Abbott)
Cipla
Dabur Pharma (Fresenius Kabi)
Daiichi Sankyo
Dalim BioTech
Dr Reddy’s Laboratory
Ebewe Pharma (Novartis)
Eden Biopharm Group
Egis
Elder Pharmaceuticals (Torrent Pharmaceuticals)
Eli Lilly
Elyson Pharmaceuticals
EMS Sigma Pharma
Eurofarma Laboratories
Farmacias Similares
Fenwal (Fresenius Kabi)
Forest Laboratories (Actavis)
Foshan Chanbende Development
Fougera Pharmaceuticals (Novartis)
Fresenius Kabi
Fresenius SE & Co
Fuji Pharma
Gedeon Richter
Genfar S.A (Sanofi)
Genzyme (Sanofi)
Gilead Sciences
GlaxoSmithKline (GSK)
Greenstone (Pfizer)
Grupo Sanborns
Grupo Uriach
Hospira (Pfizer)
IDEV Technologies (Abbott)
Ilsung Pharmaceuticals
InnoPharma Inc
Itero Biopharmaceuticals
Janssen
Javelin Pharmaceuticals (Hospira)
Kmart
KMS Pharmaceutical
Kowa Pharmaceuticals
Krka
Labesfal Genéricos (Fresenius Kabi)
Laboratorio Sanderson (Fresenius Kabi)
Laboratorios Best
Laboratorios Kendrick (Sanofi)
Lek (Novartis)
Lupin
Mayne Pharma (Hospira)
Medley (Sanofi)
Merck KGaA
MN Pharma (Amgen)
Momenta Pharmaceuticals
Mylan
Natco Pharma
Nexus Pharmaceuticals
Nichi-Iko
Nippon Chemiphar
Novartis (Sandoz)
Novo Nordisk
OptiMedica (Abbott)
Orchid Chemicals & Pharmaceuticals
Oriel Therapeutics (Novartis)
Parenteral Drugs India Ltd
Perrigo
Pfizer
Piramal (Abbott Laboratories)
Pliva (Teva)
PT Soho Global Health
Ranbaxy (Sun Pharmaceuticals)
Rimsa
Roche
Sabex (Novartis)
Sanofi
Sawai Pharmaceuticals
Schein Pharmaceutical (Actavis)
Shelys (Aspen)
Sigma Pharmaceuticals (Aspen)
Solvay Pharmaceuticals (Abbott)
Specifar Pharmaceuticals (Actavis)
STADA Arzneimittel
Sun Pharma
Synthon
Takeda
Taiyo Pharmaceuticals
Teuto Brasileiro (Pfizer)
Teva
The Laboratory Of Analytical Services International Ltd
Towa
UDL Laboratories
Uteron Pharma (Actavis)
Valeant Pharmaceuticals
Wal-Mart
Warner Chilcott (Actavis)
Wockhardt
Wyeth (Pfizer)
Zentiva (Sanofi)
Zhejiang Chiral Medicine Chemicals Co. Ltd
Zhejiang Hisun Pharmaceutical
Zydus Cadila
Organisations Mentioned in the Report
Assogenerici [Italy]
Blue Cross Blue Shield Association (BCBSA) [US]
British Generic Manufacturers Association (BGMA)
Caisse Nationale de l’Assurance Maladie (CNAM) [France]
Center for Drug Evaluation and Research (CDER) [US]
Centers for Medicare and Medicaid Services [US]
China Food and Drug Administration (CFDA)
COFEPRIS [Mexico]
Competion and Markets Authority (CMA) [UK]
Congressional Budget Office (CBO) [US]
European Commission
European Generics Medicines Association (EGA)
European Medicines Agency (EMA)
European Patent Office (EPO)
Federal Trade Commission (FTC) [US]
Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
Food and Drugs Administration (FDA) [US]
Gesundheitsberichterstattung des Bundes (Federal Health Monitoring System, Germany)
General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]
General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]
Medicine and Healthcare products Regulatory Agency (MHRA)
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Ministry of Human Resources and Social Security (MOHRSS)
National Development and Reform Commission (NDRC)
National Health Service (NHS)
National Pharmaceutical Pricing Authority [India]
Pan American Health Organization (PAHO)
Pharmaceutical and Medical Devices Agency (PMDA) [Japan]
Queen Mary University of London
Servicio Sanitario Nazionale (SSN) [Italy]
United Nations’ Department of Economic and Social Affairs
US Generic Pharmaceutical Association (GPhA)
Veropharm (Abbott)
World Health Organization (WHO)
World Trade Organisation (WTO)
Download sample pages
Complete the form below to download your free sample pages for Generic Drugs Market Forecast 2016-2026Download sample pages
Complete the form below to download your free sample pages for Generic Drugs Market Forecast 2016-2026Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
What are the dynamic growth sectors? where are the regional business opportunities?
Which technologies will prevail and who are the leading companies succeeding in these sectors and why?
If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.
If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/
Latest Pharma news
Visiongain Publishes Dermatological Drugs Market Report 2021-2031
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
Visiongain Publishes Antigen Skin Test Market Report to 2031
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
12 January 2021
Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.
11 January 2021
Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021